This recent readout follows successful data from another combination including Braftovi in mCRC.

NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...

Pfizer (NYSE:PFE) reported that its BRAFTOVI combination therapy produced significant progression free survival benefits in ...

Pfizer announces positive results from pivotal BREAKWATER trial of Braftovi in combo with cetuximab & Folfiri in patients with metastatic colorectal cancer: New York Wednesday, Fe ...

Pfizer (NYSE:PFE) reported positive topline Phase 3 results from its BREAKWATER oncology trial in metastatic colorectal ...

Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...

Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...

BRAF-positive non-small cell lung cancer (NSCLC) treatments can use the BRAF biomarker to provide effective, targeted treatment for this subset of lung cancer. BRAF-positive NSCLC is an uncommon or ...

University of Queensland researchers have found that a genetic mutation that causes melanoma can lie dormant in healthy skin, a finding that could improve screening of areas more prone to the disease.